Company Shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) Drops by -2.28%

Peregrine Pharmaceuticals (NASDAQ:PPHM) : During the past 4 weeks, traders have been relatively bearish on Peregrine Pharmaceuticals (NASDAQ:PPHM), hence the stock is down -13.83% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.52% relative to the S&P 500. The 4-week change in the price of the stock is -12.44% and the stock has fallen -2.28% in the past 1 week.

The company shares have dropped -70.45% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $1.38 and the one year low was seen on May 9, 2016. The 50-Day Moving Average price is $0.42 and the 200 Day Moving Average price is recorded at $0.60.

The stock has recorded a 20-day Moving Average of 3.47% and the 50-Day Moving Average is 2.16%.


Peregrine Pharmaceuticals (NASDAQ:PPHM): stock turned positive on Friday. Though the stock opened at $0.3904, the bulls momentum made the stock top out at $0.4 level for the day. The stock recorded a low of $0.3804 and closed the trading day at $0.39, in the green by 2.60%. The total traded volume for the day was 626,761. The stock had closed at $0.3801 in the previous days trading.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.